Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine.
about
Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedsideThe use of a physiologically based pharmacokinetic model to evaluate deconvolution measurements of systemic absorptionPhosphorylation of nucleoside analog antiretrovirals: a review for clinicians.Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children.Clinical pharmacokinetics of alamifovir and its metabolites.Preclinical aspects of lamivudine and famciclovir against hepatitis B virus.Profound suppression of hepatitis B virus replication with lamivudine.Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adultsPopulation pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials.A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.The triple combination indinavir-zidovudine-lamivudine is highly synergistic.Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis BDiagnosis and management of pre-core mutant chronic hepatitis B.Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction.Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis.Developmental pharmacokinetic changes of Lamivudine in infants and childrenCombination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infantsPharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure.Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.The role of formulation on the pharmacokinetics of antiretroviral drugs.Pharmacokinetic considerations in the use of antivirals in neonates.Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products.Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study.Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption.Determination of drug absorption rate in time-variant disposition by direct deconvolution using beta clearance correction and end-constrained non-parametric regression.
P2860
Q24622161-DD20FBF2-E61A-4E33-ACB6-0C1B17C50785Q24793037-88EE9012-9360-4385-8D5B-094FD51D2887Q31975873-5B50FF2F-E661-431D-99E5-473C78B5A127Q33703360-D819FDC5-C940-42F6-9870-6DAF0C94A09EQ33770064-B4F1E20A-713D-436A-AEAD-23B345F4910FQ33801322-55C579ED-98E4-40BF-A93E-0F0896A60A86Q33947154-356A25D3-E80E-4DA5-BE99-BD1881115C4FQ33976449-A0568047-45AB-49B9-A245-371683E3F6A5Q33978372-121D1009-652B-4A26-88A0-89047D1A73D7Q33978917-6701535C-4DCC-4C88-A7D4-05DD7B67179EQ33979237-D2332A75-9E8C-4A6E-8200-601D11758B1EQ34233156-A0F9F1DF-E2BD-45BD-9815-53450486A05AQ34368364-BB05EB85-BCCA-463D-8C80-6062B24B8797Q35125144-42BF88FB-A8EB-4871-A721-2CF8D015D70EQ35233168-BED36B3B-E2A4-4024-A608-49E838517030Q35388475-14CEC3F1-AAC9-4204-9821-DA07AE2D499CQ35803067-ADC1E058-5D8C-4D9D-8BD8-C32A81AE4DC5Q36013430-0F81F069-D2BB-4DE1-A19E-DD34229396D7Q36097686-8F2983CD-D9B2-42A3-AAA2-F2BF6552B226Q36313247-824C14C3-4E4B-4B51-8B6C-D435627CCDB3Q36379850-04FF0698-03EE-4F9C-9978-E2055E2CA8F2Q37731863-86CA4371-8306-40DA-B2D2-278255F5FFDFQ38216047-BA7B8AAA-2AE9-4077-9EC1-1B663C4D0ABFQ38624965-B72570CE-AC63-4DCB-AE33-E0A9DFB36525Q38771392-A22A65FC-8BE3-477F-8DBB-C519E251E2EBQ43554149-3544A30C-1196-489E-B0DB-6688C39B37FFQ46930423-DFB4E9CF-B978-4737-8FAB-8ACBFA98655BQ49908214-7C2C317E-0316-444C-BD08-11F9637E5512Q51563075-6E592174-0854-4759-8C33-172947114776Q51967246-830398B3-A294-44B0-B24C-FF3E2EDAE31D
P2860
Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine.
@en
Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine.
@nl
type
label
Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine.
@en
Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine.
@nl
prefLabel
Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine.
@en
Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine.
@nl
P2093
P2860
P1476
Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine.
@en
P2093
P2860
P304
P356
10.1002/J.1552-4604.1995.TB04043.X
P577
1995-12-01T00:00:00Z